Nominations for Appointment to the Grants Working Group (GWG)

NEW APPOINTMENTS

Shondra Pruett-Miller, PhD
Associate Member, St. Jude Children's Research Hospital

Referral: Dr. Pruett-Miller was identified by Dr. Hayley Lam.

Expertise Relevance to CIRM GWG: Dr. Pruett-Miller's expertise with core facilities and stem cell models will be invaluable in reviewing Infrastructure program applications.

Prior Service in CIRM Reviews: N/A

Bio:
Dr. Shondra Pruett-Miller is an Associate Member in the Department of Cell and Molecular Biology, the Founding Director of the Center for Advanced Genome Engineering (CAGE), and the Associate Director of Shared Resources for the Comprehensive Cancer Center at St. Jude Children's Research Hospital in Memphis, Tennessee. Shondra completed her Ph.D. in Cell and Molecular Biology from The University of Texas Southwestern Medical Center in August 2008. While at UT Southwestern, she worked in Matthew Porteus' lab on the optimization of zinc finger nucleases for use in mammalian cells. After graduate school, she was recruited to Sigma-Aldrich as a Senior Scientist in R&D working on their CompoZr ZFN technology. In 2012, she returned to academia as the Founder and Director of the Genome Engineering and iPSC Center (GEiC) at Washington University School of Medicine in St. Louis. In 2017, she joined the Faculty at St. Jude Children's Research Hospital where she established and is directing the Center for Advanced Genome Engineering (CAGE). Shondra has overseen the creation of over 1000 custom edited clonal cell lines, more than 350 custom edited preclinical animal models, and over 100 custom pooled gRNA screens.

Premal Lulla, MBBS, MS
Associate Professor, Baylor College of Medicine

Referral: Dr. Lulla was identified by Dr. Adrian Gee.

Expertise Relevance to CIRM GWG: Dr. Lulla's expertise in hematology/oncology will be invaluable in reviewing Discovery, Translational and Clinical program applications.

Prior Service in CIRM Reviews: Dr. Lulla has served as a specialist in Discovery and Clinical program reviews.

Bio:
Dr. Premal Lulla is Associate Professor of Medicine at Baylor College of Medicine, Houston, TX. At Baylor, he also serves as Laboratory Medical Director (cGMP) at the Center for Cell and Gene Therapy and serves on the Graduate School Faculty focused on Translational Biology and Molecular Medicine. He is a hematopoietic stem cell transplant physician-scientist focused on improving the outcomes of patients with hematological malignancies. Clinically, he cares for patients with relapsed or refractory hematological malignancies including myeloma who undergo cellular therapies and transplantation. His research focuses on developing innovative T cell immunotherapies for patients with hematological malignancies such as myeloma using both gene-modified and non-gene modified approaches, as well as studying the correlates of clinical response, toxicities and mechanisms of immune evasion after cancer immunotherapy.

Dr. Lulla earned his MBBS at DY Patil Medical College, Mumbai, Maharashtra. He completed his residency in internal medicine, his clinical fellowship in hematology/oncology, his research fellowship in cellular therapy, and his MS in Clinical Investigation at Baylor College of Medicine. He has clinically translated vaccine-based and adoptive T cell therapies and he is currently the principal investigator (PI) of eight ongoing trials and a co-investigator of fifteen additional investigator-initiated "first-in-human" cellular immunotherapy clinical trials. He is also PI on two biobanking protocols for tissue samples from patients with chemotherapy refractory and immunotherapy refractory hematological malignancies, which has enabled several collaborations across basic, translational and clinical scientists focused on improving upon existing therapeutics for these patients. Among other services, he is engaged in shaping national-level committees such as ASH, ASTCT, CIBMTR, BMT-CTN, FACT focused on establishing cellular therapy as a standard of care for a variety of disorders. He serves as Clinical and Marrow Collections Inspector for the Foundation for the Accreditation of Cellular Therapy (FACT), and also serves on the Education Committee and Clinical Outcomes Committee of FACT. He also serves on the CAR T Steering Committee of the Association of American Cancer Institutes which aims to help guide and implement CAR T-cell therapy programs at AACI member centers across North America. Among many honors, he has received the Young Investigator Award from the American Society for Blood and Marrow Transplantation (now ASTCT), the Early Career Clinical Investigator Award from the Cancer Prevention & Research Institute of Texas Scholar (CPRIT), and he has been recognized multiple times with the Fellows Teaching Award through the Houston Methodist Fellowship program.

Richard Maziarz, MD
Professor of Medicine, Oregon Health and Science University

Referral: Dr. Maziarz was identified by Dr. Linda Nevin.

Expertise Relevance to CIRM GWG: Dr. Maziarz's expertise in blood/bone marrow transplantation and immune effector cell therapies will be invaluable in reviewing Clinical and Translational program applications.

Prior Service in CIRM Reviews: Dr. Maziarz has served as a specialist in Clinical program reviews.

Bio:
Dr. Richard Maziarz is Professor of Medicine and Director of the Adult Blood & Marrow Transplantation & Immune Effector Cell Therapy Programs at Oregon Health and Science University. He is a hematologist-oncologist, skilled in blood and bone marrow transplantation, hematologic malignancies (leukemia, lymphoma, myeloma), immunology, stem cell and other cell therapies, and health economics (particularly reimbursements and costs of care). His major research interests include molecular immunology, blood and bone marrow transplantation, graft vs. host disease, and stem cells/regenerative medicine with research efforts at the basic, translational and clinical levels. Recently, he has been focused on the toxicity and efficacy of immune effector cell therapy as well as potential expanded indications for cellular therapy.

Dr. Maziarz earned his MD from Harvard Medical School. He completed his residency at University Hospitals of Cleveland, his research fellowship in Immunology at the Dana-Farber Cancer Institute, his research/clinical fellowship in Hematology at Brigham and Women's Hospital, his research fellowship in medicine at Harvard Medical School, and his clinical fellowship in Medical Oncology at Dana-Farber Cancer Institute. He has over 300 publications, holds patents related to multipotent adult progenitor cells and their uses, and is often recognized as one of Portland's Best Doctors and Castle Connelly Top Doctors for Cancer. He has served as Chair of the NMDP financial working group for their system capacity initiative regarding transplantation expansion and subsequently, as Chair of the Health Economics Interest Group for ASTCT. Among other activities, he serves on the Steering Committee of the BMT CTN, Editorial Board of *Cytotherapy, Bone Marrow Transplantation*, and is Associate Editor of the *Journal of Transplantation & Cell Therapy* and the "Current Hematologic Malignancies Reviews" for *Transplantation*; he is currently participating on data and safety monitoring boards related to acute myeloid leukemia, CAR T-cell therapies and acute thrombotic CVA; and he recently has been appointed to the US Department of Health & Human Services Health Resources and Services Administration, Advisory Council on Blood Stem Cell Transplantation, wherein he is also chair of the Committee on Drug Shortages.

Pauline McEwan, PhD
Senior Consultant, Biologics Consulting

Referral: Dr. McEwan was identified by Dr. Chris Scull.

Expertise Relevance to CIRM GWG: Dr. McEwan's expertise in regulatory affairs will be invaluable in reviewing Clinical and Translational program applications.

Prior Service in CIRM Reviews: Dr. McEwan has served as a specialist on Clinical and Translational program reviews.

Bio:
Dr. Pauline McEwan is a Senior Consultant at Biologics Consulting. Her main focus at Biologics Consulting is to assist clients in achieving the goal of commercial success throughout the development process from early to late-stage strategic planning, guidance and navigating complex regulatory issues. She is an American Board-Certified Toxicologist with 18 years of experience as a consultant in nonclinical development within a broad range of therapeutic areas. Specifically, she has experience with combination product development of drug-device combinations for cardiovascular, oncology, CNS, ocular and respiratory indications, and she has significant expertise in cell and gene therapies for cardiovascular, CNS and orphan indications (enzyme deficiencies, genetically inherited disorders) with knowledge of gain-of-function approaches. More recently, she has worked on monoclonal antibody development for oncology indications, immunological, enzyme and regenerative medicine therapeutics. She also focuses on both early and late-stage development paths involving nonclinical IND, NDA, BLA authoring and oversight, including 510K and PMAs in conjunction with CMC and device teams.

Dr. McEwan earned her PhD in Experimental Pathology from the University of Glasgow Department of Pathology and MRC Blood Pressure Unit. She held post-doctoral fellowships in pharmacology and cardiovascular genetics at Edinburgh and Harvard Medical School, respectively. For several years, she served as Principal Consultant for a cardiovascular gene therapy company and was responsible for the nonclinical development of a gene therapy program for congestive heart failure, working in conjunction with FDA on developing guidance documents for industry. Prior to her consulting career, Pauline held industry positions as senior manager and director of research and development at two California-based cardiovascular companies developing intracardiac combination products. Prior to joining Biologics Consulting, she served as a senior consultant toxicologist at two consulting companies where she was involved in all aspects of nonclinical development of gene and cell therapies, small molecule, biosimilars, and viral therapeutics, as well as drug and device development and safety programs. Her work has culminated in several publications in peer-reviewed journals and book chapters.

Manal Morsy, MD, PhD, MBA
Executive Vice President, Head of Global Regulatory Affairs, Athersys

Referral: Dr. Manal Morsy was identified by Drs. Abla Creasey and Hayley Lam.

Expertise Relevance to CIRM GWG: Dr. Morsy's expertise in regulatory affairs will be invaluable in reviewing Clinical and Translational program applications.

Prior Service in CIRM Reviews: Dr. Morsy has served as a specialist in Clinical program reviews.

Bio:
Dr. Manal Morsy is Executive Vice President and Head of Global Regulatory Affairs at Athersys Inc., a biotechnology company focused on developing novel therapies, particularly in regenerative medicine, for medical conditions where there is significant clinical need. She is responsible for the global regulatory activities of Athersys, including the US, EU, and Japan, building up capabilities for BLA/NDA/MAA/JNDA/WMA eCTD submissions to support portfolio development in therapeutic programs involving cell therapy, oncology, graft versus host disease (GvHD), solid organ transplant, cardiovascular, neurology, ophthalmology, digestive/ulcerative colitis, immunology, peripheral vascular disease and rare (orphan) disorders. In the US alone, she has overseen successful achievement of multiple orphan designations, fast track designations for HIV, TB, GvHD, ARDS and ischemic stroke programs, and RMAT designation for MultiStem (an adult-derived "off-the-shelf" stem cell therapy platform) in the treatment of ischemic stroke and acute respiratory distress syndrome.

Dr. Morsy earned her MD degree from the University of Alexandria in Egypt; her PhD in Molecular Biology and Biomedical Sciences from the Eastern Virginia Medical School/Old Dominion University in Norfolk, VA; and her MBA from LeBow Business School, Drexel University in Philadelphia, PA. She completed a postdoctoral fellowship in Human Genetics at Eastern Virginia Medical School and additional fellowships in Diagnostics and Gene Therapy at Baylor College of Medicine. Prior to joining Merck, J&J, PTC Therapeutics and for the past decade Athersys. She served as Vice President at PTC Therapeutics, Inc. where she led global regulatory affairs and developed the company's regulatory capabilities in several therapeutic areas, including neurology (Duchenne muscular dystrophy), pulmonary (cystic fibrosis), hematology/oncology, metabolic and rare disorders. Prior to joining PTC, Dr. Morsy served as Senior Director, Global Regulatory Affairs, at Tibotec/J&J, where she was responsible for global regulatory activities for the company's pediatric development programs, the tuberculosis program, and the HIV (Prezista)

program. Prior to Tibotec, Dr. Morsy served as Director of Worldwide Regulatory Affairs for Merck & Co., where she led and supported new regulatory filings in the US and abroad for vaccines and biologics. Dr. Morsy has several scientific publications and reviews in peer reviewed journals, including *Nature Biotechnology, The Journal of Clinical Investigation (JCI), Proceedings of the National Academy of Sciences (PNAS), The Journal of the American Medical Association (JAMA),* and *Annual Review of Medicine (ARM).*

Jennifer Moore, PhD
Head of Cellular Services, Sampled

Referral: Dr. Moore was identified by Dr. Shyam Patel.

Expertise Relevance to CIRM GWG: Dr. Moore's expertise in stem cell models, repository and genomics resource, and cell and data repositories will be invaluable in reviewing Infrastructure program applications.

Prior Service in CIRM Reviews: N/A

Bio:
Dr. Jennifer Moore is the Head of Cellular Services at Sampled, in New Jersey. She has more than 15 years of experience growing and differentiating human pluripotent stem cells. She has studied cardiac and neural differentiation, focusing on the signaling pathways controlling differentiation into these tissues. In the progress of these studies, she has gained experience in genetic modification of these cells, has developed and optimized differentiation protocols and has developed molecular based assays to characterize the pluripotency and fidelity of the stem cells and to characterize the resulting differentiated cells.

Dr. Moore earned her PhD from the University of North Carolina at Chapel Hill in Biochemistry and Biophysics and her graduate research focused on the role of the cell cycle in the early development of sea urchins. Dr. Moore then joined Dr. Christine Mummery's lab at the Hubrecht Laboratory in Utrecht, the Netherlands, where she studied the role of protein signaling in the cardiac differentiation of human embryonic stem cells (hESC). She continued her post-doctoral studies in the field of human embryonic stem cell derived cardiomyocytes at the University of California, Davis, focusing on the use of genetic strategies to drive chamber- specific cardiomyocyte differentiation. In 2007, Dr. Moore became the Assistant Director of the Rutgers University Stem Cell Core. In 2010, she joined the RUCDR as the Associate Director of the RUCDR Stem Cell Laboratory, followed by Director in 2018. When Rutgers University spun out RUCDR into a private company in 2020, she became the Senior Director of the Stem Cell Laboratory. In all these roles, Dr. Moore oversaw the derivation, banking and QC of iPSC source cells and the generation, banking, QC and editing of iPSC at RUCDR and then Sampled. In 2021, Dr. Moore became Head of Cellular Services where she oversees all cell processing at Sampled.

Scott Noggle, PhD
Senior Vice President, Research, The New York Stem Cell Foundation

Referral: Dr. Noggle was identified by Dr. Shyam Patel.

Expertise Relevance to CIRM GWG: Dr. Noggle's expertise in high throughout systems and stem cell models for Alzheimer's disease and Parkinson's disease will be invaluable in reviewing Infrastructure program applications.

Prior Service in CIRM Reviews: N/A

Bio:
Dr. Scott Noggle is the Senior Vice President, Research at The New York Stem Cell Foundation (NYSCF). He leads the NYSCF Research Institute, overseeing all stem cell research programs. With a long-standing interest in the derivation and use of human stem cells to understand human development and disease, Dr. Noggle applies new advances in pluripotent stem cell biology and cell reprogramming to the creation of human models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease to discover new disease targets. He also directs a group at the NYSCF Research Institute developing large-scale automated systems that use stem cells as a tool to understand how genetics impact susceptibility to these diseases. He and his team have developed high throughput automated systems for deriving new stem cell lines and differentiated cells to study disease models from large numbers of patients in parallel. Dr. Noggle earned his MS in Immunology at the University of Arkansas at Fayetville and his PhD in Molecular Medicine at the Medical College of Georgia.

REAPPOINTMENTS

CIRM is seeking the reappointment of the individuals listed in the table below. Their updated biographies follow.

Proposed Reappointments to GWG

Last	First	Term	Years	Expertise
Andrews	Brenda	3	6	Genomics; Phenomics; Cell Cycle Regulated Transcription
Saha	Krishanu	2	4	Gene Editing; Biomanufacturing; Disease Modeling; Reprogramming
Scull	Christopher	2	4	Design and Management of IND-enabling Studies; Pre-clinical Regulatory Strategy
Shah	Khalid	2	4	Neuro-Oncology; Targeted Cancer Therapeutics, Stem Cell Transplantation, Gene Editing and Engineering
Whiteside	Theresa	3	6	Cancer Immunology and Immunotherapy; Cellular Therapy, Immunoregulation; Immunopathology

Brenda Andrews, PhD
Dr. Brenda Andrews is University Professor at the Donnelly Centre at the University of Toronto. She is a geneticist recognized for her functional genomics work in the budding yeast model system. She is known particularly for her studies on cell cycle-regulated transcription and protein kinase function in yeast and for pioneering work with Charles Boone on genetic networks. Her research focuses on systems biology, functional genomics, genetic networks, cell cycle and signaling, and transcription networks.

Dr. Andrews graduated from the University of Toronto with a PhD in Medical Biophysics in and pursued postdoctoral training in genetics with the late Dr. Ira Herskowitz at the University of California San Francisco. She was subsequently recruited to the Department of Medical Genetics (now Molecular Genetics) at the University of Toronto. She served as Chair of the Department for 5 years before assuming a position as Chair of the Banting & Best Department of Medical Research and as the inaugural Director of the Donnelly Centre. She continued as Director of the Donnelly Centre and Charles H Best Chair of Medical Research until 2020, and currently holds a Tier 1 Canada Research Chair in Systems Genetics & Cell Biology. Dr. Andrews was named a University Professor in 2017, a designation that recognizes pre-eminence in a particular field of knowledge and is held by no more than two percent of the tenured faculty. She is also a Companion of the Order of Canada, an elected Fellow of the Royal Society of Canada, the American Association for the Advancement of Science and the American Academy of Microbiology, and an International Member of the National Academy of Sciences (USA). Dr. Andrews serves on many editorial and scientific advisory boards, including founding Editor-in-Chief of *G3*, an open access journal of the Genetics Society of America. She is currently a member of the Board of Directors of the Burroughs Wellcome Fund, the Vice Chair of the European Molecular Biology Laboratory (EMBL) Scientific Advisory Committee, a member of the Governing Council of the Canadian Institutes for Health Research (CIHR) and the Scientific Advisory Board of the Cancer Research UK City of London (CRUK CoL) Centre, among other activities.

Dr. Andrews has served on the GWG for almost 10 years. She has reviewed for Education programs as well as Research Leadership and Genomics Centers awards.

Krishanu Saha, MPhil, PhD
Dr. Krishanu Saha is an Associate Professor of Biomedical Engineering and Medical History & Bioethics at the University of Wisconsin-Madison. He is also a member of the Wisconsin Institute for Discovery, the Carbone Cancer Center, and the Stem Cell and Regenerative Medicine Center. His lab focuses on genome editing (particularly CRISPR-Cas9 and nanoparticle delivery), biomanufacturing (with projects involving monitoring and controlling the heterogeneity during gene modification and scale-up of stem cells and T cell immunotherapies), disease modeling (using customized biomaterials and genome editing to generate new human cell-based models of inherited disorders) and science policy/bioethics (to understand how novel emergent biotechnologies intersect with law and policy). Major thrusts of his lab involve gene editing and cell engineering of human cells found in the retina, central nervous system, liver, and blood. His lab has developed a wide array of engineering approaches that seek to generate new cells,

organoids and tissues from patient samples, as well as a suite of gene-editing technologies to knockout, correct or insert transgenes into human cells.

Dr. Saha earned his BS in Chemical Engineering at Cornell University, his MPhil in Biotechnology at University of Cambridge, and his PhD in in Chemical Engineering at the University of California, Berkeley where he trained in the labs of David Schaffer and Kevin Healy. Dr. Saha was a Society in Science: Branco-Weiss fellow at the Whitehead Institute for Biomedical Research at MIT in the lab of Rudolf Jaenisch and in the in the Science and Technology Studies program at Harvard University with Professor Sheila Jasanoff. He has published over 90 scientific manuscripts, filed several patents, and received awards including the National Science Foundation CAREER Award, the Biomedical Engineering Society's Rising Star Award, and the Gund Harrington Scholar Award. Among other services, he is the Kathryn and Latimer Murfee Chair of the Retina Research Foundation (which aims to reduce retinal blindness worldwide by funding programs in research and education), a member of the National Academies' Forum on Regenerative Medicine, a member of the Coordinating Committee of the NIH Somatic Cell Genome Editing Consortium, leader of the gene therapy biomanufacturing impact area of the Grainger Institute for Engineering, and co-lead for the T cell testbed within the National Science Foundation's Center for Cell Manufacturing Technologies (CMaT). He is a member of the ASGCT and ISSCR Ethics Committees.

Dr. Saha has served on the GWG for almost 6 years. He has reviewed for Discovery and Translational stage programs as well as the COVID-19 offerings.

Christopher Scull, PhD, PMP, RAC
Dr. Christopher Scull is a Senior Consultant at Biologics Consulting, a regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices. He has over 15 years of experience managing R&D projects spanning research, discovery, preclinical development, and regulatory affairs. He works across multiple therapeutic areas including oncology, regenerative medicine, gene therapy, hematology, inflammation, diabetes, wound healing and tissue repair, and autoimmune disease. He has worked with cell therapies, cell/tissue-device combinations, gene therapies and gene-editing products, live biotherapeutics, mAbs, antibody-drug conjugates, other modified antibodies, vaccines, other combination products, small molecules, and tissue grafts. His expertise is in the design and management of nonclinical IND-enabling pharmacology and toxicology studies, including data review and writing/auditing study reports. He also has experience in the development of small molecules and biologics, including cell and gene therapies.

Dr. Scull earned his BS in Chemistry and his PhD in Cellular and Molecular Pathology from University of North Carolina, Chapel Hill. While completing his doctoral studies, he assisted the biotech startup Entegrion with preparation and analysis of test articles for nonclinical studies and pre-approval testing of a new trauma bandage. After his doctoral studies, he worked as a Translational Research Fellow at Columbia University's Department of Medicine, leading a project studying cell death in heart disease and the impact of inflammation on macrophage function and viability. He then worked at Memorial Sloan Kettering Cancer Center to author, review, and coordinate FDA submissions on behalf of clinical and translational teams, as well as establish a GLP compliance program (including testing facility design and construction, procurement and validation of equipment, SOP development, and supervision/training staff for study management and GLP compliance in IND-enabling studies. Prior to working at Biologics Consulting, he served as Global Director of Discovery Sciences at Innovimmune Biotherapeutics where he designed and directed preclinical pharmacology and toxicology studies performed in-house and by CROs across the US, Europe, and Asia, and oversaw preclinical development and regulatory strategy for multiple drug candidates.

Dr. Scull has served on the GWG for almost 6 years. He has reviewed for Translational and Clinical stage programs as well as the COVID-19 offerings.

Khalid Shah, MS, PhD
Dr. Shah is a Professor at Harvard Medical School and the Vice Chair of Research in the Department of Neurosurgery at Brigham and Women's Hospital (BWH), as well as the Founder and Director of the Center for Stem Cell and Translational Immunotherapy and Center for Excellence in Biomedicine at BWH. He is also Principal Faculty of the Harvard Stem Cell Institute and Graduate Neuroscience Program at Harvard University. His lab focuses on developing and testing novel, targeted, cell-based therapies for brain cancers, such as repurposing cancer cells into therapeutics using CRISPR/Cas9 technology to reverse engineer them into becoming a dual-action cancer-killing vaccine. This approach aims to kill tumor cells and induce long-term immunity by training the immune system so that it can prevent cancer from recurring.

Dr. Shah earned his MS and PhD in Biotechnology /Genetic Engineering at the Wageningen University and Research Center in The Netherlands. He completed his postdoctoral fellowship in Neurology and Radiology at Massachusetts

General Hospital. He has published over 120 peer-reviewed articles, has multiple patents related to cancer treatment and cell therapies, is a reviewer for multiple scientific journals and serves on the Editorial Board of Cytotherapy, Stem Cells, Molecular Therapy, Trends in Oncology, and Cells. He also serves as a grant reviewer for multiple agencies throughout the US and Europe. He founded and serves on the Scientific Advisory Board of AMASA Therapeutics Inc., a biopharmaceutical company focused on developing novel stem cell based targeted biological therapeutics to treat cancer patients with unmet need. In addition to mentoring postdoctoral fellows, residents, medical students, graduate students, and undergraduate students from across the US and 40 foreign countries, he established an outreach program with various high schools to give high school students a glimpse of scientists' life in the laboratory. Among many honors, he has received the Research Impact and Research Idea awards from the Department of Defense for his work on treating metastatic brain tumors. His work on engineering cancer-killing cells that target solid tumors has been recognized as one of the Disruptive Dozen efforts in gene and cell therapy most likely to have significant impact on healthcare by the World Innovation Forum on Cell and Gene Therapy. He has also received the Young Investigator award from the Alliance for Cancer Gene Therapy (ACGT), a Research Fellow Award from the American Cancer Society (ACS), and the Innovator award from the James McDonnell Foundation.

Dr. Shah has served on the GWG for almost 6 years. He has reviewed for Discovery and Clinical stage programs.

Theresa Whiteside, PhD, MD_{hc}, ABMLI

Dr. Theresa Whiteside is Professor of Pathology, Immunology and Otolaryngology at University of Pittsburgh School of Medicine, and Member of the UPMC Hillman Cancer Center. Her research interests are cancer immunology and immunotherapy, cellular therapy, immunoregulation, and immunopathology. Her translational research has been focused on mechanisms of tumor-induced immunosuppression, cytokine networks, development of anticancer vaccines, immunobiology of human tumors and the role of natural immunity in the control of cancer progression. She studies mechanisms of tumor escape from the host immune system and the development of therapies designed to eliminate tumor escape in patients with HNC, melanoma, breast carcinoma and hematological malignancies. Most recently, she has been investigating tumor-derived exosomes (TEX) and their role in cancer-induced immune suppression.

Dr. Whiteside received both her MA and PhD degrees in Microbiology from Columbia University, New York, NY. She is a Diplomate of the American Board of Medical Laboratory Immunology (1979). She was as a Fogarty Senior International Fellow at the Ludwig Institute for Cancer Research in Lausanne, Switzerland (1984-85). At the University of Pittsburgh, Dr. Whiteside rose through the faculty ranks to become Professor of Pathology with secondary appointments as Professor of Immunology and Otolaryngology (1989-present). She served as Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the UPMC Hillman Cancer Center for 25 years. She has authored 650 peer-reviewed papers and 180 chapters and review articles. She devotes much of her time to training young physicians in doing research in cancer immunology and maintains scientific collaborations with many former students. Her current research is supported by two awards from the US National Institutes of Health (NIH). She received a Honoris causa degree in Medicine from The Poznan Medical University in Poland in 2011 and was awarded a Richard V. Smalley Memorial Award by the Society of Immunotherapy of Cancer in 2012.

Dr. Whiteside served on the GWG for 12 years. She has reviewed for Discovery, Translational, and Clinical stage programs and the COVID-19 offerings.